Impact of Bebtelovimab Treatment Timing on COVID-19 Outcomes in Ambulatory Solid Organ Transplant Recipients.

Transpl Infect Dis · 2025 · PMC11827732 · PMID 39549258

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Given the trend to lower bebtelovimab treatment among Black patients, we performed sensitivity analyses to further assess the impact of being Black versus all other races on EBT + LBT versus NBT (aOR, 0.603 [95% CI, 0.343–1.059]; p = 0.078) and EBT versus NBT (aOR, 0.557 [95% CI, 0.298–1.1041]; p = 0.066), that did not reach statistical significance. 4.3.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.